196 related articles for article (PubMed ID: 19786980)
41. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
[TBL] [Abstract][Full Text] [Related]
42. Importance of xeroderma pigmentosum group D polymorphisms in susceptibility to ovarian cancer.
Costa S; Pinto D; Pereira D; Vasconcelos A; Afonso-Lopes C; Osório T; Lopes C; Medeiros R
Cancer Lett; 2007 Feb; 246(1-2):324-30. PubMed ID: 16677755
[TBL] [Abstract][Full Text] [Related]
43. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.
Le Morvan V; Smith D; Laurand A; Brouste V; Bellott R; Soubeyran I; Mathoulin-Pelissier S; Robert J
Pharmacogenomics; 2007 Dec; 8(12):1693-703. PubMed ID: 18085999
[TBL] [Abstract][Full Text] [Related]
44. Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients.
Nairuz T; Bushra YU; Kabir Y
Asian Pac J Cancer Prev; 2021 Dec; 22(12):3809-3815. PubMed ID: 34967559
[TBL] [Abstract][Full Text] [Related]
45. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients.
Morari EC; Lima AB; Bufalo NE; Leite JL; Granja F; Ward LS
J Cancer Res Clin Oncol; 2006 Aug; 132(8):521-8. PubMed ID: 16788846
[TBL] [Abstract][Full Text] [Related]
46. The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma.
Erčulj N; Kovač V; Hmeljak J; Dolžan V
Ann Oncol; 2012 Apr; 23(4):961-7. PubMed ID: 21765044
[TBL] [Abstract][Full Text] [Related]
47. Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer.
Zhang BL; Sun T; Zhang BN; Zheng S; Lü N; Xu BH; Wang X; Chen GJ; Yu DK; Lin DX
Chin Med J (Engl); 2011 Jan; 124(2):199-204. PubMed ID: 21362365
[TBL] [Abstract][Full Text] [Related]
48. 'Genetic profiling' and ovarian cancer therapy (review).
Vella N; Aiello M; Russo AE; Scalisi A; Spandidos DA; Toffoli G; Sorio R; Libra M; Stivala F
Mol Med Rep; 2011; 4(5):771-7. PubMed ID: 21687948
[TBL] [Abstract][Full Text] [Related]
49. [Correlation of polymorphisms in xeroderma pigmentosum group C to the risk of ovarian carcinoma].
Zhou RM; Wang N; Guo W
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jan; 29(1):91-2. PubMed ID: 18785488
[No Abstract] [Full Text] [Related]
50. [Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients from Yakutia].
Кhokhrin DV; Khrunin AV; Ivanova FG; Moiseev AA; Gorbunova VA; Limborskaia SA
Mol Gen Mikrobiol Virusol; 2013; (4):6-9. PubMed ID: 24645271
[TBL] [Abstract][Full Text] [Related]
51. Genetic explanation for cisplatin-induced ear damage.
Senior K
Lancet Oncol; 2007 Mar; 8(3):195. PubMed ID: 17354296
[No Abstract] [Full Text] [Related]
52. Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
Roco A; Cayún J; Contreras S; Stojanova J; Quiñones L
Front Genet; 2014; 5():391. PubMed ID: 25452763
[TBL] [Abstract][Full Text] [Related]
53. Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins.
Khrunin A; Ivanova F; Moisseev A; Khokhrin D; Sleptsova Y; Gorbunova V; Limborska S
Pharmacogenomics; 2012 Jan; 13(2):171-8. PubMed ID: 22188361
[TBL] [Abstract][Full Text] [Related]
54. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms.
Tzvetkov MV; Behrens G; O'Brien VP; Hohloch K; Brockmöller J; Benöhr P
Pharmacogenomics; 2011 Oct; 12(10):1417-27. PubMed ID: 21902499
[TBL] [Abstract][Full Text] [Related]
55. Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.
Giovannetti E; Pacetti P; Reni M; Leon LG; Mambrini A; Vasile E; Ghidini M; Funel N; Lucchesi M; Cereda S; Peters GJ; Cantore M
Pharmacogenomics; 2011 Dec; 12(12):1641-52. PubMed ID: 22026922
[TBL] [Abstract][Full Text] [Related]
56. Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.
Henríquez-Hernández LA; Murias-Rosales A; González-Hernández A; de León AC; Díaz-Chico N; Fernández-Pérez L
Cancer Epidemiol; 2010 Oct; 34(5):634-8. PubMed ID: 20638924
[TBL] [Abstract][Full Text] [Related]
57. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
Huang MY; Huang ML; Chen MJ; Lu CY; Chen CF; Tsai PC; Chuang SC; Hou MF; Lin SR; Wang JY
Pharmacogenet Genomics; 2011 Jan; 21(1):18-25. PubMed ID: 21057378
[TBL] [Abstract][Full Text] [Related]
58. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.
Khrunin AV; Khokhrin DV; Moisseev AA; Gorbunova VA; Limborska SA
Pharmacogenomics; 2014 Feb; 15(3):329-37. PubMed ID: 24533712
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
